BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
C4 Therapeutics (CCCC) Gets a Buy From Stifel Nicolaus
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), C4 Therapeutics (CCCC) and Lineage Therap (LCTX)
BMO Capital Reiterates Outperform on C4 Therapeutics, Maintains $20 Price Target
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Raises Target Price to $20
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and C4 Therapeutics (CCCC)
Buy Rating on C4 Therapeutics: Key Clinical Milestones and Drug Candidate Potential
Morgan Stanley Remains a Hold on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
C4 Therapeutics Analyst Ratings
C4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable Financials